Changes in packaging can reduce suicide rates. With Utah's rising number of overdose deaths and suicides, this small change ...

today announced that the company has launched Elite's generic version of Norco® (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets.

About The Study: This cohort study among individuals participating in a weight loss program found that nearly half of those consuming alcohol at baseline decreased their alcohol use after anti-obesity ...

announced this month that it got through the final hurdles with the U.S. Food and Drug Administration to get approval for a clinical study to look at veterans’ “real-world” cannabis use.

A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a midstage study, but fell short of the loftier expectations of some investors.

Blockbuster weight loss drugs created to treat type 2 diabetes appear to help patients with a host of other medical conditions – and now, doctors can add kidney disease to the list. GLP-1 ...

(Rosenbluth, 11/25) Stat: Roche Drug Fails In Lung Cancer, Raising Questions About Its Target An experimental cancer treatment from Roche failed to improve survival in a major lung cancer study, the ...

Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly obesity drug MariTide. Despite the medication demonstrating the ability ...

The year-long trial involving 592 people tested several different doses of the drug as a monthly or bi-monthly injection. Amgen said it also planned to study quarterly dosing. Novo's Wegovy led to ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study ...

Billions of dollars worth of investment have flowed into obesity drug research over the past two years, drawn by the success of Wegovy and Zepbound as well as forecasts that have predicted $100 ...

the majority of those taking the drugs are not confident they can maintain the improvement after ending treatment, according to a new report. In a study of 500 patients by weight loss management ...